Financhill
Sell
31

GMED Quote, Financials, Valuation and Earnings

Last price:
$61.06
Seasonality move :
4.41%
Day range:
$60.23 - $61.12
52-week range:
$54.48 - $94.93
Dividend yield:
0%
P/E ratio:
45.56x
P/S ratio:
3.37x
P/B ratio:
2.02x
Volume:
1.2M
Avg. volume:
1.7M
1-year change:
-5.2%
Market cap:
$8.3B
Revenue:
$2.5B
EPS (TTM):
$1.34

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
GMED
Globus Medical
$625.9M $0.74 16.49% 239.13% $84.00
ATEC
Alphatec Holdings
$168.2M -$0.12 22.9% -86.45% $18.21
BSX
Boston Scientific
$4.6B $0.67 18.78% 229.2% $116.78
ENOV
Enovis
$558.9M $0.74 5.83% 1731.46% $56.50
ITGR
Integer Holdings
$428.7M $1.24 6.46% 76.23% $147.88
PODD
Insulet
$543.3M $0.79 25.32% -63.95% $324.57
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
GMED
Globus Medical
$61.05 $84.00 $8.3B 45.56x $0.00 0% 3.37x
ATEC
Alphatec Holdings
$13.03 $18.21 $1.9B -- $0.00 0% 2.93x
BSX
Boston Scientific
$106.66 $116.78 $157.8B 77.85x $0.00 0% 9.05x
ENOV
Enovis
$35.48 $56.50 $2B -- $0.00 0% 0.92x
ITGR
Integer Holdings
$121.45 $147.88 $4.2B 57.56x $0.00 0% 2.45x
PODD
Insulet
$325.84 $324.57 $22.9B 58.60x $0.00 0% 10.96x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
GMED
Globus Medical
-- 2.870 -- 2.60x
ATEC
Alphatec Holdings
118.58% 1.134 36.81% 1.54x
BSX
Boston Scientific
33.49% 1.029 7.48% 0.68x
ENOV
Enovis
34.64% 1.134 63.52% 0.99x
ITGR
Integer Holdings
43.46% 1.567 30% 1.99x
PODD
Insulet
56.03% 1.663 9.18% 3.24x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
GMED
Globus Medical
$402.7M $98.1M 4.22% 4.59% 16.4% $136.2M
ATEC
Alphatec Holdings
$116M -$31.7M -31.36% -691.37% -26.09% -$16.7M
BSX
Boston Scientific
$3.2B $937M 6.35% 9.57% 19.02% $277M
ENOV
Enovis
$332.2M -$42.9M -18.51% -26.77% -8.62% -$44.9M
ITGR
Integer Holdings
$120.3M $55.8M 2.85% 4.85% -0.02% $6.1M
PODD
Insulet
$409M $88.8M 15.79% 36.9% 10.07% $48.1M

Globus Medical vs. Competitors

  • Which has Higher Returns GMED or ATEC?

    Alphatec Holdings has a net margin of 12.62% compared to Globus Medical's net margin of -30.68%. Globus Medical's return on equity of 4.59% beat Alphatec Holdings's return on equity of -691.37%.

    Company Gross Margin Earnings Per Share Invested Capital
    GMED
    Globus Medical
    67.33% $0.54 $4.1B
    ATEC
    Alphatec Holdings
    68.56% -$0.35 $462.5M
  • What do Analysts Say About GMED or ATEC?

    Globus Medical has a consensus price target of $84.00, signalling upside risk potential of 37.59%. On the other hand Alphatec Holdings has an analysts' consensus of $18.21 which suggests that it could grow by 39.74%. Given that Alphatec Holdings has higher upside potential than Globus Medical, analysts believe Alphatec Holdings is more attractive than Globus Medical.

    Company Buy Ratings Hold Ratings Sell Ratings
    GMED
    Globus Medical
    5 5 0
    ATEC
    Alphatec Holdings
    6 1 0
  • Is GMED or ATEC More Risky?

    Globus Medical has a beta of 1.324, which suggesting that the stock is 32.371% more volatile than S&P 500. In comparison Alphatec Holdings has a beta of 1.062, suggesting its more volatile than the S&P 500 by 6.249%.

  • Which is a Better Dividend Stock GMED or ATEC?

    Globus Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alphatec Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Globus Medical pays -- of its earnings as a dividend. Alphatec Holdings pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios GMED or ATEC?

    Globus Medical quarterly revenues are $598.1M, which are larger than Alphatec Holdings quarterly revenues of $169.2M. Globus Medical's net income of $75.5M is higher than Alphatec Holdings's net income of -$51.9M. Notably, Globus Medical's price-to-earnings ratio is 45.56x while Alphatec Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Globus Medical is 3.37x versus 2.93x for Alphatec Holdings. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    GMED
    Globus Medical
    3.37x 45.56x $598.1M $75.5M
    ATEC
    Alphatec Holdings
    2.93x -- $169.2M -$51.9M
  • Which has Higher Returns GMED or BSX?

    Boston Scientific has a net margin of 12.62% compared to Globus Medical's net margin of 14.45%. Globus Medical's return on equity of 4.59% beat Boston Scientific's return on equity of 9.57%.

    Company Gross Margin Earnings Per Share Invested Capital
    GMED
    Globus Medical
    67.33% $0.54 $4.1B
    BSX
    Boston Scientific
    68.84% $0.45 $33.6B
  • What do Analysts Say About GMED or BSX?

    Globus Medical has a consensus price target of $84.00, signalling upside risk potential of 37.59%. On the other hand Boston Scientific has an analysts' consensus of $116.78 which suggests that it could grow by 9.49%. Given that Globus Medical has higher upside potential than Boston Scientific, analysts believe Globus Medical is more attractive than Boston Scientific.

    Company Buy Ratings Hold Ratings Sell Ratings
    GMED
    Globus Medical
    5 5 0
    BSX
    Boston Scientific
    23 3 0
  • Is GMED or BSX More Risky?

    Globus Medical has a beta of 1.324, which suggesting that the stock is 32.371% more volatile than S&P 500. In comparison Boston Scientific has a beta of 0.685, suggesting its less volatile than the S&P 500 by 31.536%.

  • Which is a Better Dividend Stock GMED or BSX?

    Globus Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Globus Medical pays -- of its earnings as a dividend. Boston Scientific pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios GMED or BSX?

    Globus Medical quarterly revenues are $598.1M, which are smaller than Boston Scientific quarterly revenues of $4.7B. Globus Medical's net income of $75.5M is lower than Boston Scientific's net income of $674M. Notably, Globus Medical's price-to-earnings ratio is 45.56x while Boston Scientific's PE ratio is 77.85x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Globus Medical is 3.37x versus 9.05x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    GMED
    Globus Medical
    3.37x 45.56x $598.1M $75.5M
    BSX
    Boston Scientific
    9.05x 77.85x $4.7B $674M
  • Which has Higher Returns GMED or ENOV?

    Enovis has a net margin of 12.62% compared to Globus Medical's net margin of -10.02%. Globus Medical's return on equity of 4.59% beat Enovis's return on equity of -26.77%.

    Company Gross Margin Earnings Per Share Invested Capital
    GMED
    Globus Medical
    67.33% $0.54 $4.1B
    ENOV
    Enovis
    59.45% -$0.98 $4B
  • What do Analysts Say About GMED or ENOV?

    Globus Medical has a consensus price target of $84.00, signalling upside risk potential of 37.59%. On the other hand Enovis has an analysts' consensus of $56.50 which suggests that it could grow by 59.25%. Given that Enovis has higher upside potential than Globus Medical, analysts believe Enovis is more attractive than Globus Medical.

    Company Buy Ratings Hold Ratings Sell Ratings
    GMED
    Globus Medical
    5 5 0
    ENOV
    Enovis
    7 1 0
  • Is GMED or ENOV More Risky?

    Globus Medical has a beta of 1.324, which suggesting that the stock is 32.371% more volatile than S&P 500. In comparison Enovis has a beta of 1.583, suggesting its more volatile than the S&P 500 by 58.325%.

  • Which is a Better Dividend Stock GMED or ENOV?

    Globus Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Enovis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Globus Medical pays -- of its earnings as a dividend. Enovis pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios GMED or ENOV?

    Globus Medical quarterly revenues are $598.1M, which are larger than Enovis quarterly revenues of $558.8M. Globus Medical's net income of $75.5M is higher than Enovis's net income of -$56M. Notably, Globus Medical's price-to-earnings ratio is 45.56x while Enovis's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Globus Medical is 3.37x versus 0.92x for Enovis. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    GMED
    Globus Medical
    3.37x 45.56x $598.1M $75.5M
    ENOV
    Enovis
    0.92x -- $558.8M -$56M
  • Which has Higher Returns GMED or ITGR?

    Integer Holdings has a net margin of 12.62% compared to Globus Medical's net margin of -5.14%. Globus Medical's return on equity of 4.59% beat Integer Holdings's return on equity of 4.85%.

    Company Gross Margin Earnings Per Share Invested Capital
    GMED
    Globus Medical
    67.33% $0.54 $4.1B
    ITGR
    Integer Holdings
    27.51% -$0.66 $2.8B
  • What do Analysts Say About GMED or ITGR?

    Globus Medical has a consensus price target of $84.00, signalling upside risk potential of 37.59%. On the other hand Integer Holdings has an analysts' consensus of $147.88 which suggests that it could grow by 21.76%. Given that Globus Medical has higher upside potential than Integer Holdings, analysts believe Globus Medical is more attractive than Integer Holdings.

    Company Buy Ratings Hold Ratings Sell Ratings
    GMED
    Globus Medical
    5 5 0
    ITGR
    Integer Holdings
    6 2 0
  • Is GMED or ITGR More Risky?

    Globus Medical has a beta of 1.324, which suggesting that the stock is 32.371% more volatile than S&P 500. In comparison Integer Holdings has a beta of 1.030, suggesting its more volatile than the S&P 500 by 3.045%.

  • Which is a Better Dividend Stock GMED or ITGR?

    Globus Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Integer Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Globus Medical pays -- of its earnings as a dividend. Integer Holdings pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios GMED or ITGR?

    Globus Medical quarterly revenues are $598.1M, which are larger than Integer Holdings quarterly revenues of $437.4M. Globus Medical's net income of $75.5M is higher than Integer Holdings's net income of -$22.5M. Notably, Globus Medical's price-to-earnings ratio is 45.56x while Integer Holdings's PE ratio is 57.56x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Globus Medical is 3.37x versus 2.45x for Integer Holdings. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    GMED
    Globus Medical
    3.37x 45.56x $598.1M $75.5M
    ITGR
    Integer Holdings
    2.45x 57.56x $437.4M -$22.5M
  • Which has Higher Returns GMED or PODD?

    Insulet has a net margin of 12.62% compared to Globus Medical's net margin of 6.22%. Globus Medical's return on equity of 4.59% beat Insulet's return on equity of 36.9%.

    Company Gross Margin Earnings Per Share Invested Capital
    GMED
    Globus Medical
    67.33% $0.54 $4.1B
    PODD
    Insulet
    71.88% $0.50 $3B
  • What do Analysts Say About GMED or PODD?

    Globus Medical has a consensus price target of $84.00, signalling upside risk potential of 37.59%. On the other hand Insulet has an analysts' consensus of $324.57 which suggests that it could fall by -0.39%. Given that Globus Medical has higher upside potential than Insulet, analysts believe Globus Medical is more attractive than Insulet.

    Company Buy Ratings Hold Ratings Sell Ratings
    GMED
    Globus Medical
    5 5 0
    PODD
    Insulet
    14 3 0
  • Is GMED or PODD More Risky?

    Globus Medical has a beta of 1.324, which suggesting that the stock is 32.371% more volatile than S&P 500. In comparison Insulet has a beta of 1.263, suggesting its more volatile than the S&P 500 by 26.336%.

  • Which is a Better Dividend Stock GMED or PODD?

    Globus Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insulet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Globus Medical pays -- of its earnings as a dividend. Insulet pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios GMED or PODD?

    Globus Medical quarterly revenues are $598.1M, which are larger than Insulet quarterly revenues of $569M. Globus Medical's net income of $75.5M is higher than Insulet's net income of $35.4M. Notably, Globus Medical's price-to-earnings ratio is 45.56x while Insulet's PE ratio is 58.60x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Globus Medical is 3.37x versus 10.96x for Insulet. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    GMED
    Globus Medical
    3.37x 45.56x $598.1M $75.5M
    PODD
    Insulet
    10.96x 58.60x $569M $35.4M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Ginkgo Bioworks Stock a Good Buy?
Is Ginkgo Bioworks Stock a Good Buy?

Biotech innovator Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) has had better…

Why Mobileye Might Be Wall Street’s Next Big Surprise
Why Mobileye Might Be Wall Street’s Next Big Surprise

The trend to automate vehicles started long ago when adding…

Why Is Rigetti Stock Going Up?
Why Is Rigetti Stock Going Up?

Quantum computing firm Rigetti Computing (NASDAQ:RGTI) has been one of…

Stock Ideas

Buy
70
Is MSFT Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 39x

Buy
71
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 46x

Sell
46
Is AAPL Stock a Buy?

Market Cap: $3.1T
P/E Ratio: 35x

Alerts

Buy
99
SOC alert for May 20

Sable Offshore [SOC] is up 14.35% over the past day.

Buy
52
RGC alert for May 20

Regencell Bioscience Holdings [RGC] is down 10.93% over the past day.

Sell
40
GWLIF alert for May 20

Great-West Lifeco [GWLIF] is down 10.31% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock